CytRx (CYTR) Announces Presentation of Phase 2 Results for Tamibartoene at ASH Meeting
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
